NF1 gene and neurofibromatosis 1

American Journal of Epidemiology

Volumn 151, Issue 1, 2000, Pages 33-40

  Rasmussen, Sonja A ^a   Friedman, J M ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Neurofibromatosis; Neurofibromatosis 1

Indexed keywords

AUTOSOMAL DOMINANT DISORDER; CANCER SUSCEPTIBILITY; CHROMOSOME 17Q; CLINICAL FEATURE; GENE MUTATION; LIFE EXPECTANCY; NEUROFIBROMATOSIS; PENETRANCE; PHENOTYPE; PREVALENCE; REVIEW;

EID: 0033941724     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a010118     Document Type: Review

References (59)

1. Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201.
2. Wallace MR, Marchuk DA, Anderson LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181-6.
3. Li Y, O'Connell P, Breidenbach HH, et al. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995;25:9-18.
4. Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990;63:835-41.
5. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995;11:90-2.
6. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997;336:1713-20.
7. Huson SM, Compston DAS, Clark P, et al. A genetic study of von Recklinghausen neurofibromatosis in southeast Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989;26:704-11.
8. Lázaro C, Ravella A, Gaona A, et al. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994;331:1403-7.
9. Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis. 2nd ed. Baltimore, MD: The Johns Hopkins University Press, 1992.
10. Jadayel D, Fain P, Upadhyaya M, et al. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature 1990;343:558-9.
11. Stephens K, Kayes L, Riccardi VM, et al. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 1992;88:279-82.
12. Lázaro C, Gaona A, Ainsworth P, et al. Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients. Hum Genet 1996;98:696-9.
13. Upadhyaya M, Ruggieri M, Maynard J, et al. Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet 1998;102:591-7.
14. Dublin S, Riccardi VM, Stephens K. Methods for rapid detection of a recurrent nonsense mutation and documentation of phenotypic features in neurofibromatosis type 1 patients. Hum Mutat 1995;5:81-5.
15. National Institutes of Health Consensus Development Conference. Neurofibromatosis: conference statement. Arch Neurol 1988;45:575-8.
16. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7.
17. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1728 patients. Am J Med Genet 1997;70:138-43.
18. Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41:143-9.
19. Stevenson DA, Birch PH, Friedman JM, et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 1999;84:413-19.
20. North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997;48:1121-7.
21. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986;314:1010-15.
22. Poyhonen M, Niemela S, Herva R. Risk of malignancy and death in neurofibromatosis. Arch Pathol Lab Med 1997;121:139-43.
23. Cohen BH, Kaplan AM, Packer RJ. Management of intracranial neoplasms in children with neurofibromatosis type 1 and 2. The Children's Cancer Study Group. Pediatr Neurosurg 1990-91;16:66-72.
24. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994;70:969-72.
25. Garty BZ, Laor A, Danon YL. Neurofibromatosis type 1 in Israel: survey of young adults. J Med Genet 1994;31:853-7.
26. Zöller M, Rembeck B, Åkesson HO, et al. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1: a twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol 1995;75:136-40.
27. Zöller M, Rembeck B, Oden A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79:2125-31.
28. Bunin GR, Needle M, Riccardi VM. Paternal age and sporadic neurofibromatosis 1: a case-control study and consideration of the methodologic issues. Genet Epidemiol 1997;14:507-16.
29. Carey JC, Laub JM, Hall BD. Penetrance and variability in neurofibromatosis: a genetic study of 60 families. Birth Defects Orig Art Ser 1979;15:271-81.
30. Cnossen MH, van der Est MN, Breuning MH, et al. Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1? Hum Mutat 1997;9:458-64.
31. Leppig KA, Kaplan P, Viskochil D, et al. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 1997;73:197-204.
32. Tonsgard JH, Yelavarthi KK, Cushner S, et al. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 1997;73:80-6.
33. Rasmussen SA, Colman SD, Ho VT, et al. Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet 1998;35:468-71 .
34. Allanson JE, Upadhyaya M, Watson GH, et al. Watson syndrome: is it a subtype of type 1 neurofibromatosis? J Med Genet 1991;28:752-6.
35. Tassabehji M, Strachan T, Sharland M, et al. Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome. Am J Hum Genet 1993;53:90-5.
36. Charrow J, Listernick R, Ward K Autosomal dominant multiple café-au-lait spots and neurofibromatosis-1: evidence of non-linkage. Am J Med Genet 1993;45:606-8.
37. Brunner HG, Hulsebos T, Steijlen PM, et al. Exclusion of the neurofibromatosis 1 locus in a family with inherited café-au-lait spots. Am J Med Genet 1993;46:472-4.
38. Abeliovich D, Gelman-Kohan Z, Silverstein S, et al. Familial café-au-lait spots: a variant of neurofibromatosis type 1. J Med Genet 1995;32:985-6.
39. Pulst SM, Riccardi VM, Fain P, et al. Familial spinal neurofibromatosis: clinical and DNA linkage analysis. Neurology 1991;41:1923-7.
40. Poyhonen M, Leisti E-L, Kytola S, et al. Hereditary spinal neurofibromatosis: a rare form of NF1 ? J Med Genet 1997;34: 184-7.
41. Legius E, Wu R, Eyssen M, et al. Encephalocraniocutaneous lipomatosis with a mutation in the NF1 gene. J Med Genet 1995;32:316-19.
42. Hager CM, Cohen PR, Tschen JA. Segmental neurofibromatosis: case reports and review. J Am Acad Dermatol 1997;37: 864-9.
43. Colman SD, Rasmussen SA, Ho VT, et al. Somatic mosaicism in a patient with neurofibromatosis type 1. Am J Hum Genet 1996;58:484-90.
44. Ainsworth PJ, Chakraborty PK, Weksberg R. Example of somatic mosaicism in a series of de novo neurofibromatosis type 1 cases due to a maternally derived deletion. Hum Mutat 1997;9:452-7.
45. Wu BL, Boles RG, Yaari H, et al. Somatic mosaicism for deletion of the entire NF1 gene identified by FISH. Hum Genet 1997;99:209-13.
46. Colley A, Donnai D, Evans DGR. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 1996;49:59-64.
47. Carey JC. Neurofibromatosis-Noonan syndrome. Am J Med Genet 1998;75:263-4.
48. Easton DF, Ponder MA, Huson SM, et al. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993; 53:305-13.
49. Riccardi VM. Genotype, malleotype, phenotype, and randomness: lessons from neurofibromatosis-1 (NF-1). Am J Hum Genet 1993;53:301-4.
50. Heim RA, Kam-Morgan LNW, Binnie CG, et al. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet 1995;4:975-81.
51. Park VM, Pivnick EK. Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients. J Med Genet 1998;35:813-20.
52. Lázaro C, Gaona A, Ravella A, et al. Prenatal diagnosis of neurofibromatosis type 1: from flanking RFLPs to intragenic microsatellite markers. Prenat Diagn 1995;15:129-34.
53. Wolkenstein P, Freche B, Zeller J, et al. Usefulness of screening investigations in neurofibromatosis type 1: a study of 152 patients. Arch Dermatol 1996;132:1333-6.
54. Cnossen MH, Smit FJ, de Goede-Bolder A, et al. Diagnostic delay in neurofibromatosis type 1. EurJ Pediatr 1997;156:482-7.
55. Crowe FW, Schull WJ, Neel JV. A clinical, pathological, and genetic study of multiple neurofibromatosis. Springfield, IL: Charles C Thomas, 1956.
56. Sergeyev AS. On the mutation rate of neurofibromatosis. Humangenetik 1975;28:129-38.
57. Samuelsson B, Axelsson R. Neurofibromatosis. A clinical and genetic study of 96 cases in Gothenburg, Sweden. Acta Derm Venereol Suppl (Stockh) 1981;95:67-71.
58. Fuller LC, Cox B, Gardner RJM. Prevalence of von Recklinghausen neurofibromatosis in Dunedin, New Zealand. Neurofibromatosis 1989;2:278-83.
59. Clementi M, Barbujani G, Turolla L, et al. Neurofibromatosis-1: a maximum likelihood estimation of mutation rate. Hum Genet 1990;84:116-18.